November 02, 2025

Get In Touch

Viral Infections Linked To Reduced Survival Among Women With Ovarian Cancer

In a groundbreaking study, scientists have delved into the intricate relationship between infectious agents and the outcomes of high-grade serous epithelial ovarian cancer, a crucial but poorly understood aspect of the disease. The study revealed a significant association between the presence of viruses of interest (VOI) and lower overall survival, shedding light on potential implications for the clinical management of ovarian cancer. The study results were published in the journal PLOS One.

Early 20th-century findings established a link between infectious agents and cancer. Presently, 11 agents are recognized as carcinogenic. About 16% of global cancer cases may be linked to viruses, including HPV in ovarian tumors. The association's significance in high-grade serous ovarian cancer was explored in a single-institution cohort. Hence, in a quest to understand and shed light on the link between infectious agents and ovarian cancer, employing a comprehensive analysis of viral DNA in primary ovarian cancer tumors and its correlation with clinical outcomes was carried out through a cohort study.
Also Read: Letrozole may increase gestational diabetes risk during Frozen Embryo Transfer in Women With PCOS
Unveiling the Viral Landscape, Researchers meticulously examined archived tumors from 98 patients diagnosed with high-grade serous epithelial ovarian cancer, spanning from January 1, 1994, to December 31, 2010. Leveraging advanced Luminex technology, they identified polymerase chain reaction-amplified viral DNA for a diverse set of 113 specific viruses. Statistical methods, including logistic regression and Cox proportional hazards models, were applied to assess the associations between tumor viral status, disease outcome, and overall survival (OS).

Results:
Viruses of Interest: The findings revealed that almost half of the cases (45.9%) contained at least one virus. Six highly prevalent viruses, designated as viruses of interest (VOI), emerged as key players linked to clinical outcomes. These included Epstein-Barr virus 1, Merkel cell polyomavirus, human herpes virus 6b, and human papillomaviruses 4, 16, and 23.
Overall Survival rates: Significantly, the presence of VOI and platinum sensitivity were independently associated with OS. The median OS was notably reduced in tumors exhibiting VOI compared to those without (22 vs. 44 months). Distinctly, women below 70 years old with VOI in tumors displayed significantly lower median OS compared to age-matched counterparts without VOI (20 vs. 57 months). However, among women aged 70 or older, there was no discernible difference in OS based on tumor virus status.
Also Read: Long Covid linked to Cardiac Complications among covid survivors
Thus, the study's groundbreaking findings underscore a significant association between the presence of viruses of interest and lower overall survival in ovarian cancer patients. This revelation holds promise for potential implications in the clinical management of ovarian cancer. However, researchers emphasize the need for additional studies to comprehensively validate and understand the broader implications of these findings in the realm of ovarian cancer treatment. As the scientific community unravels the viral connection, these insights may pave the way for novel approaches to enhance outcomes and refine strategies for managing this complex disease.
Further reading: Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and correlation with clinical outcomes. https://doi.org/10.1371/journal.pone.0294448

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!